Ingen internetforbindelse — viser den gemte version af siden.

Mesoblast Ltd

USUSD
← Til screeneren

Mesoblast Ltd (AU:MSB) — Biotechnology: Biological Products (No Diagnostic Substances). Antal børser, hvor selskabets aktier handles: 2. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om virksomheden

Websted
mesoblast.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hovedkontor
MELBOURNE, VICTORIA, Australia
Administrerende direktør
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Ansatte
108
Udestående aktier
1.3 mia. pr. 2026-06-30
Free float
861.1 mio.
Markedsværdi
1.48 mia. USD
Insidere
36.28%
Institutionelle investorer
17.44%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
AU000000MSB8
Beskrivelse

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Børser og tickere

BørsTickerValutaPrisType
US USA StocksMEOBFUSD1.39 +21.93%almindelige aktier
AU Australian Securities ExchangeMSBAUD—almindelige aktier

Kurs over 3 måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Ingen udbyttebetalinger fundet (tjekket 07.10.2026). Virksomheden udbetaler sandsynligvis ikke udbytte.

Nyheder denne uge

Endnu ingen nyheder fra virksomhedens websted.

annonce

Største ejere

EjerAndelAktierRapportdato
Itescu (Silviu) (Chief E…≈6.23%80.84 mio.2026-07-17
VANGUARD STAR FUNDS-Vang…1.05%13.66 mio.2026-04-30
VANGUARD TAX-MANAGED FUN…0.62%8.01 mio.2026-06-30
iShares Trust-iShares Co…0.53%6.88 mio.2026-07-31
Rose (Eric) (Director (N…≈0.52%6.75 mio.2026-01-09
DFA INVESTMENT TRUST CO-…0.36%4.68 mio.2026-04-30
VANGUARD Intl Eqy. INDEX…0.27%3.51 mio.2026-04-30
iShares Trust-iShares MS…0.24%3.07 mio.2026-07-31
SCHWAB STRATEGIC TRUST-S…0.15%1.99 mio.2026-05-31
Dimensional ETF Trust-Di…0.11%1.38 mio.2026-04-30
iShares Trust-iShares Co…0.09%1.23 mio.2026-07-31
SPDR INDEX SHARES Fd.S-S…0.09%1.19 mio.2026-08-31
Bell (Jane Catherine) (D…≈0.05%622 4922025-02-28
Burns (William) (Indepen…≈0.02%226 2502025-10-21
Legato Capital Managemen…0.01%47 3802022-06-30
Cobley (Lyn Elizabeth) (…≈0%63 0002026-01-09